NGlycolylGM3/VSSP vaccine in metastatic breast cancer patients: Results of phase I/IIa clinical trial

Breast Cancer: Basic and Clinical Research

Volumn 6, Issue 1, 2012, Pages 151-157

  de la Torre, Ana ^a   Hernandez, Julio ^a   Ortiz, Ramón ^a   Cepeda, Meylán ^a   Perez, Kirenia ^b   Car, Adriana ^b   Viada, Carmen ^b   Toledo, Darién ^b   Guerra, Pedro Pablo ^c   García, Elena ^c   Arboláez, Migdacelys ^c   Fernandez, Luis E ^b  

^a Celestino Hernández Hospital   (Cuba)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^c National Center of Clinical Trials   (Cuba)

Author keywords

Clinical trial; Ganglioside; Metastatic breast cancer; NGcGM3; Therapeutic vaccine

Indexed keywords

CANCER VACCINE; GANGLIOSIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; ADVANCED CANCER; AGED; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE PAIN; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; COLLOID CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FATIGUE; FLU LIKE SYNDROME; HUMAN; HUMAN TISSUE; HYPOTENSION; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; METASTASIS; MYALGIA; NAUSEA; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; SURVIVAL TIME; SWEATING; VOMITING;

EID: 84867029555     PISSN: None     EISSN: 11782234     Source Type: Journal    
DOI: 10.4137/BCBCR.S8488     Document Type: Article

References (14)

1. Sankaranarayanan R, Swaminathan R, Lucas E. Ed. Cancer survival in Africa, Asia, the Caribbean and Central America (SurvCan). IARC Scientific Publications Vol. 162. Lyon: International Agency for Research on Cancer; 2011.
2. Cancer incidence in female population aged 15 and over as prime locations and age groups. National Cancer Registry in Cuba. 2009.
3. National Cancer Institute: PDQ® Breast Cancer Treatment. Bethesda, MD: National Cancer Institute. Date last modified June 7, 2011. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional. Accessed Novembre 8, 2011.
4. Pronzato P, Rondini M. First line chemotherapy of metastatic breast cancer. Ann Oncol. 2006;17 Suppl 5:v165-8.
5. Andre F, Slimane K, Bachelot T, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J of Clin Oncol. 2004;22(16):3302-3308.
6. Moulder SL, Craft BS, Hortobagyi GN. Inhibition of receptor tyrosine kinases in combination with chemotherapy for the treatment of breast cancer. Anticancer Agents Med Chem. 2008;8(5):481-487.
7. Ito Y, Miura H. Combined chemotherapy with molecular-targeted agent for breast cancer. Gan To Kagaku Ryoho. 2008;35(5):731-736
8. Mulens V, Marinello P, Carr A, Mazorra Z, Fernández LE. Gangliósidos en la Biología e Inmunoterapia del Cáncer: la Experiencia Cubana. Cancerología. 2009;4:155-167.
9. De León J, Fernández A, Clavell M, et al. La variante N-glicolilada del gangliósido GM3 en la biología de los tumores: un blanco atractivo para la inmunoterapia del cáncer. Biotecnología Aplicada. 2008;25(2):161-165.
10. Díaz A, Alfonso M, Alonso R, et al. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol. 2003;107:80-89.
11. Blanco R, Rengifo E, Rengifo Ch, Cedeño M, Frómeta M, Carr A. Immunohistochemical reactivity of the 14F7 monoclonal antibody raised against N-Glycolyl GM3 ganglioside in some benign and malignant skin neoplasms. ISRN Dermatology. 2011.
12. Marquina G, Waki H, Fernandez LE, et al. Gangliosides expressed in human breast cancer. Cancer Res. 1996;56(22):5165-5171.
13. Mulens V, de la Torre A, Marinello P, et al. Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients. Hum Vaccin. 2010 Sep 14;6(9) [Epub ahead of print]
14. Ensayo Clínico: Vacuna NGcGM3/VSSP/Montanide ISA 51 en cancer de mama IIa, IIb y IIIa operadas con ganglios positivos y libres de enfermedad. Fase IIb/III. Código: RPCEC 00000070. Registro Público Cubano de Ensayos Clínicos. CENCEC. Registro Primario de la OMS. Disponible en: http://registroclinico.sld.cu/ensayos/RPCEC00000070-Sp.